成人肥胖患者使用 7.2 mg 司美格鲁肽达到可持续减重阈值所需时间：STEP UP 试验的事后分析.pdf

1、Argyrakopoulou G et al.Presented at the 33rdEuropean Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Time to sustainable weight reduction thresholds with semaglutide 7.2 mg in adults with obesity:A post hoc analysis of the STEP UP trialGeorgia Argyrakopoulou1,Christine S.Fuchs Jacobsen2,Swath

2、i Gopal3,Deborah B.Horn4,Maria Quiroga2,John B.Buse51Diabetes and Obesity Unit,Athens Medical Center,Athens,Greece;2Novo Nordisk A/S,Sborg,Denmark;3Novo Nordisk Global Business Services,Bangalore,India;4Center for Obesity Medicine and Metabolic Performance,University of Texas McGovern Medical School

3、,Houston,Texas,USA;5Division of Endocrinology,University of North Carolina School of Medicine,Chapel Hill,North Carolina,USAThis study was sponsored by Novo Nordisk A/S and is registered with ClinicalTrials.gov(NCT05646706)Medical writing support was provided by Sophie Walton,MSc CMPP,of Apollo,and

4、Natasha Tracey-Curran PhD,a contract writer working on behalf of Apollo,OPEN Health Communications,and funded by Novo Nordisk A/S,in accordance with Good Publication Practice(GPP)guidelines(ismpp.org/gpp-2022)Scan QR code or visit the web site below for:https:/ presentation portalArgyrakopoulou G et

5、 al.Presented at the 33rd European Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Disclosures Georgia Argyrakopoulou has received research grants and/or consulting fees from Menarini Diagnostics,Novo Nordisk,and Pharmaserve-Lilly;and has acted as a speaker for Novo Nordisk,Pharmaserve-Lilly,

6、Boehringer Ingelheim,Menarini Diagnostics,AstraZeneca,Libytec Pharmaceutical,Hemoglobe,Medtronic,Win Medica and AbbottArgyrakopoulou G et al.Presented at the 33rd European Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Introduction1.Wharton S et al.Lancet Diabetes Endocrinol 2025;13:949936.T